Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Cara Therapeutics

Cara Therapeutics reported $16.68M in Current Liabilities for its fiscal quarter ending in March of 2023.

Current Liabilities Change
Acadia Pharmaceuticals ACAD:US USD 224.3M 98.67M
Cara Therapeutics CARA:US USD 16.68M 6.78M
Chugai Pharma 4519:JP JPY 315.15B 108.58B
Depomed DEPO:US USD 94.54M 771K
Endo International ENDP:US USD 606.64M 82.98M
Halozyme Therapeutics HALO:US USD 91.92M 38.87M
Horizon Pharma HZNP:US USD 884.89M 64.25M
J&J JNJ:US USD 60.37B 4.57B
Neurocrine Biosciences NBIX:US USD 374.1M 163.6M
Pacira PCRX:US USD 98.7M 49.08M
RedHill Biopharma RDHL:US USD 197.45M 3.92M
Revance Therapeutics RVNC:US USD 77.98M 2.3M
Supernus Pharmaceuticals SUPN:US USD 731.54M 43.59M
Vanda Pharmaceuticals VNDA:US USD 93.79M 2.36M